摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[3-(4-chlorobenzyl)-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-5-yloxy]acetic acid tert-butyl ester | 1221181-25-4

中文名称
——
中文别名
——
英文名称
[3-(4-chlorobenzyl)-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-5-yloxy]acetic acid tert-butyl ester
英文别名
Tert-butyl 2-[3-[(4-chlorophenyl)methyl]-1,4-dimethyl-2-oxoquinolin-5-yl]oxyacetate
[3-(4-chlorobenzyl)-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-5-yloxy]acetic acid tert-butyl ester化学式
CAS
1221181-25-4
化学式
C24H26ClNO4
mdl
——
分子量
427.928
InChiKey
MLOFHXWFDSIUFQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    申请人:Aissaoui Hamed
    公开号:US20100113531A1
    公开(公告)日:2010-05-06
    The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R 1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.
    本发明涉及式(I)的新噻唑啉衍生物,其中A和R1如描述中所述,以及它们作为药物的使用,尤其是作为食欲素受体拮抗剂的使用。
  • [EN] QUINOLIN-2-ONE COMPOUNDS<br/>[FR] COMPOSÉS DE QUINOLIN-2-ONE
    申请人:ARGENTA ORAL THERAPEUTICS LTD
    公开号:WO2010040989A1
    公开(公告)日:2010-04-15
    A compound of structural formula [1]: in which: A represents a direct bond, an optionally substituted alkylene or alkenylene group, or a group of formula Z-(optionally substituted)alkylene; B represents a direct bond, an optionally substituted alkylene or alkenylene group, or a group of formula Z-(optionally substituted)alkylene or (optionally substituted)alkylene-Z; Z represents an oxygen atom, an NH or N-alkyl group, a group of formula S(O)n, in which n = 0 to 2, or a group of formula -O-SO2-; X represents a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid or a group of formula C(=O)NHSO2W or SO2NHC(=O)W; W represents an optionally substituted aryl or heteroaryl group or an optionally substituted alkyl group; Y represents an optionally substituted aryl or heteroaryl group, or an optionally substituted aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl, aryl-fused-cycloalkyl or cycloalkyl group; Ra, Rb and Rc independently represent hydrogen, acyl, alkoxy, alkylsulphinyl, alkylsulphonyl, alkylthio, -NH2, aminoalkyl, hydroxyalkyl, arylalkyl, cyano, dialkylamino, halo, haloalkoxy, haloalkyl, alkyl, alkenyl, -OH, -CHO, -NO2, aryl (optionally substituted with alkoxy, haloalkoxy, halogen, alkyl or haloalkyl), heteroaryl (optionally substituted with alkoxy, haloalkoxy, halogen, alkyl or haloalkyl), heterocycloalkyl, aminoacyl, aminosulphonyl, acylamino, sulphonylamino, heteroarylalkyl, cyclic amine, aryloxy, heteroaryloxy, arylalkyloxy or heteroarylalkyloxy;
    结构式[1]的化合物:其中:A代表直链键,可选择取代的烷基或烯基基团,或者公式Z-(可选择取代)烷基;B代表直链键,可选择取代的烷基或烯基基团,或者公式Z-(可选择取代)烷基或(可选择取代)烷基-Z;Z代表氧原子,NH或N-烷基基团,公式S(O)n中的基团,其中n = 0至2,或者公式-O-SO2-的基团;X代表羧酸四唑3-羟基异噁唑,羟酸,膦酸酯,膦酸酰,膦酰胺,磺酸或者公式C(=O)NHSO2W或SO2NHC(=O)W的基团;W代表可选择取代的芳基或杂环芳基,或者可选择取代的烷基基团;Y代表可选择取代的芳基或杂环芳基,或者可选择取代的芳基-融合-杂环烷基,杂环芳基-融合-环烷基,杂环芳基-融合-杂环烷基,芳基-融合-环烷基或环烷基基团;Ra、Rb和Rc独立地代表氢、酰基、烷氧基、烷基磺酰基、烷基磺基、烷基基、-NH2、基烷基、羟基烷基、芳基烷基、基、二烷基基、卤素、卤代烷氧基、卤代烷基、烷基、烯基、-OH、-CHO、-NO2、芳基(可选择取代烷氧基、卤代烷氧基、卤素、烷基或卤代烷基)、杂环芳基(可选择取代烷氧基、卤代烷氧基、卤素、烷基或卤代烷基)、杂环烷基、基酰、基磺酰、酰胺基、磺酰胺基、杂环芳基烷基、环胺基、芳氧基、杂环氧基、芳基烷氧基或杂环芳基烷氧基;
  • US8236964B2
    申请人:——
    公开号:US8236964B2
    公开(公告)日:2012-08-07
  • [EN] THIAZOLIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE THIAZOLIDINE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2008117241A2
    公开(公告)日:2008-10-02
    [EN] The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.
    [FR] L'invention porte sur de nouveaux dérivés de thiazolidine de la formule (I), dans laquelle A et R1 sont tels que décrits dans la description, et sur leur utilisation comme médicaments, notamment comme antagonistes du récepteur de l'orexine.
查看更多